title: Incidence of premature discontinuation of antiplatelet therapy after sirolimus-eluting stent implantation.
abstract: BACKGROUND
  Antiplatelet therapy in patients with sirolimus-eluting stents (SES) may be stopped because of bleeding or an invasive procedure.
  
  
  RESULTS
  In 254 patients with SES, the incidence of discontinuation of antiplatelet therapy and subsequent adverse cardiac events was evaluated. Follow-up was complete for 97.2% of the population and mean follow-up was 15.6+/-8.9 months. Discontinuation of antiplatelet therapy occurred for 46 patients (18.1%): 1 case of late stent thrombosis (2.2%) occurred 10 days after cessation of therapy because of pulmonary hemorrhage 7 months after SES deployment.
  
  
  CONCLUSIONS
  Discontinuation of antiplatelet therapy in patients with SES is not infrequent.
authors.affiliation: Department of CardiovascularScience and Medicine, Chiba University Graduate School ofMedicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
authors.forename: Yo
authors.initials: Y
authors.lastname: Iwata
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Fukushima
authors.forename: Hideki
authors.initials: H
authors.lastname: Kitahara
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Asano
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishio
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakayama
authors.forename: Nakabumi
authors.initials: N
authors.lastname: Kuroda
authors.forename: Issei
authors.initials: I
authors.lastname: Komuro
mesh_terms: D000368:Aged; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015994:Incidence; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D020123:Sirolimus / Q000009:adverse effects*
chemical_list: D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D020123:Sirolimus